Bezuclastinib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable protein tyrosine kinase inhibitor of mutated forms of the tumor-associated antigen mast/stem cell factor receptor c-Kit (SCFR), with potential antineoplastic activity. Upon oral administration, bezuclastinib binds to and inhibits specific c-Kit mutants. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these c-Kit mutations. c-Kit, a transmembrane protein and receptor tyrosine kinase, is overexpressed in solid tumors and hematological malignancies; it plays a key role in the regulation of cell differentiation and proliferation.

**Synonyms:** - BEZUCLASTINIB - CGT 9486 - CGT-9486 - CGT9486 - PLX9486 - c-Kit Inhibitor PLX9486